Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Iran's stolen futures: The arrested Iranians at risk of execution by the regime - 2Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- 32024's Hot Games: Must-Play Titles of the Year
- 4Scientists reveal earliest evidence for shifting of Earth’s crust
- 5High velocity Internet services for Metropolitan Regions
- Investigating the Advantages of a Bank account: A Complete Aide
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Bolsonaro discharged from hospital and placed under house arrest
- A Manual for Nations to Head out To
- Must-Sit in front of the Programs from Europe and the US
- Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Ocean side Objections: Staggering Waterfront Breaks
